JP2011516423A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516423A5
JP2011516423A5 JP2011502108A JP2011502108A JP2011516423A5 JP 2011516423 A5 JP2011516423 A5 JP 2011516423A5 JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011516423 A5 JP2011516423 A5 JP 2011516423A5
Authority
JP
Japan
Prior art keywords
molecule
sequence
virus
item
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516423A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038636 external-priority patent/WO2009121004A2/en
Publication of JP2011516423A publication Critical patent/JP2011516423A/ja
Publication of JP2011516423A5 publication Critical patent/JP2011516423A5/ja
Pending legal-status Critical Current

Links

JP2011502108A 2008-03-28 2009-03-27 ウイルス抗原に対する中和分子 Pending JP2011516423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4045908P 2008-03-28 2008-03-28
US61/040,459 2008-03-28
PCT/US2009/038636 WO2009121004A2 (en) 2008-03-28 2009-03-27 Neutralizing molecules to viral antigens

Publications (2)

Publication Number Publication Date
JP2011516423A JP2011516423A (ja) 2011-05-26
JP2011516423A5 true JP2011516423A5 (https=) 2013-05-23

Family

ID=41021445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502108A Pending JP2011516423A (ja) 2008-03-28 2009-03-27 ウイルス抗原に対する中和分子

Country Status (8)

Country Link
US (3) US20100040635A1 (https=)
EP (2) EP2274334A2 (https=)
JP (1) JP2011516423A (https=)
CN (1) CN102046656A (https=)
AU (1) AU2009228058A1 (https=)
CA (1) CA2719201A1 (https=)
IL (1) IL208313A0 (https=)
WO (1) WO2009121004A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
AU2010303568B2 (en) 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011111966A2 (en) * 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
EP2748184A1 (en) * 2011-08-27 2014-07-02 Universität Zürich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
IN2014CN02114A (https=) 2011-09-20 2015-05-29 Sinai School Medicine
MX350282B (es) * 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
ES2686526T3 (es) 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス,インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
CN104045709B (zh) * 2013-08-02 2017-05-24 中国医学科学院病原生物学研究所 人源抗h7n9禽流感病毒中和性抗体a6、其制备方法及应用
EP3037533A4 (en) * 2013-08-23 2017-07-05 Fujita Health University Anti-influenza virus-neutralizing antibody
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
US20180008702A1 (en) 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
EA038407B1 (ru) * 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018169785A2 (en) 2017-03-13 2018-09-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Therapeutic antibodies to marburg virus
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020090747A1 (ja) * 2018-10-29 2020-05-07 株式会社免疫生物研究所 抗hiv抗体及びその製造方法
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2023092314A1 (zh) * 2021-11-24 2023-06-01 苏州方科生物科技有限公司 结合bp特异性抗原肽的人源抗体、制备方法及用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DD228737A1 (de) * 1984-11-06 1985-10-23 Inst F Angewandte Virologie Verfahren zur herstellung von influenza-inaktivimpfstoffen mit geringer stammabhaengigkeit
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
CA2388054C (en) * 1999-10-18 2012-12-11 Chiron Corporation Compositions and methods for stimulating an immune response against infectious agents
WO2001060402A2 (en) * 2000-02-15 2001-08-23 Intellivax International Inc. Proteosome influenza vaccine
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
DE60328674D1 (de) 2002-04-17 2009-09-17 Bioren Inc Universelle banken für immunoglobuline
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2004254352A1 (en) 2003-06-27 2005-01-13 Roberto Crea Look-through mutagenesis
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
JP5161882B2 (ja) * 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用
CA2675137A1 (en) 2007-01-12 2008-07-24 Sea Lane Biotechnologies, Llc. Combinatorial libraries of conformationally constrained polypeptide sequences
BRPI0809435A2 (pt) * 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
FR2916107B1 (fr) 2007-05-11 2015-11-27 Centre Nat Etd Spatiales Actionneur alternatif a asservissement en boucle fermee
WO2008153236A1 (en) 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof

Similar Documents

Publication Publication Date Title
JP2011516423A5 (https=)
Laursen et al. Broadly neutralizing antibodies against influenza viruses
JP7183149B2 (ja) 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
AU2009227567B2 (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
JP2009537147A5 (https=)
EP2652496B1 (en) Vaccine antigens that direct immunity to conserved epitopes
JP2012526839A5 (https=)
US20170136118A1 (en) Neutralizing molecules to viral antigens
JP6450688B2 (ja) 呼吸器合胞体ウイルスfタンパク質エピトープ
US9650434B2 (en) Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus
JP2010521147A5 (https=)
US11103575B2 (en) Immunogenic composition for MERS coronavirus infection
US20120009212A1 (en) Conjugates utilizing platform technology for stimulating immune response
CN103483421A (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
TWI695842B (zh) 類黃熱病毒粒子
Yewdell Viva la revolucion: rethinking influenza a virus antigenic drift
Estepa et al. Pepscan mapping and fusion-related properties of the major phosphatidylserine-binding domain of the glycoprotein of viral hemorrhagic septicemia virus, a salmonid rhabdovirus
De Jong et al. Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains
Boruah et al. Single domain antibody multimers confer protection against rabies infection
JP7634231B2 (ja) Pan-ノイラミニダーゼ阻害抗体
Stropkovská et al. Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin
CN102238963A (zh) 完全人源性流感m2特异性抗体
S Shcherbakova et al. Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope
Sastre et al. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities
JPWO2022045126A5 (https=)